GHENT – An investment consortium, with RMM (Rudi Marien) and Saffelberg (Jos Sluys) as lead investors, has invested in the new spin-off Antelope Dx. Together with some high net worth individuals, they have invested 5,1 million EUR in the new diagnostic company that develops innovative technology and applications for point-of-care testing.
The Antelope technology is the result of ten years of research at the Photonics Research Group of Ghent University. Since mid-last year, the technology has been further incubated in MyCartis and the newco is now established as a spin-off from UGent and MyCartis.
Antelope Dx develops a point-of-need diagnostics platform that allows patients, consumers and healthcare professionals to have on-the-spot access to key health parameters. The Antelope technology aims to offer clinical lab performance with the ease-of-use of a pregnancy test at a consumer price tag. The platform is based on innovative lab-on-chip technology and aims to perform high quality tests on any bodily fluid, without requiring complex user operations or sample preparation.
The first test in development is a home test to diagnose two common sexually transmitted diseases, Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG). The second test is a test for healthcare professionals to determine whether a suspected infection is of bacterial origin, and as such is an aid to reduce the over-prescription of antibiotics.
Jan-Willem Hoste, founder of Antelope Dx BV and COO, commented: “There are a vast number of domains where the technology can be disruptive. In general, we target decentralized settings where immediate information on health parameters is needed. Home-management of chronic diseases is definitely a key setting where we can make a big difference for the patient by offering lab-performance, ease-of-use, a low- price tag and connectivity. Additionally, we are looking at testing in retail clinics and doctor’s offices. We evaluate opportunities for over-the-counter tests, for lifestyle solutions and animal health testing.”
Hilde Windels, CEO of Antelope Dx said: “With its focus on fast, affordable, and accurate tests, Antelope Dx strives to bring healthcare to the consumer, the patient or the healthcare professional where and when needed. We want to expand the current, highly successful offering of glucose meters and pregnancy tests by adding a series of home tests, actionable for both patient and doctor.”
Antelope Dx is located in the BIOSCAPE incubator in Ghent-Zwijnaarde and employs approximately 15 people.
Website: www.antelopedx.com (under construction).
MyCartis has developed the immune-diagnostic technology, DMAT®, which is integrated in its real-time platform called EVALUTION®. DMAT® delivers an unmatched combination of features, covering multiplexing, assay speed and analytical performance, together with the unique ability to measure antibody binding strength and hence qualify immune responses directly. EVALUTION® uses a 16-channel disposable cartridge. It is currently used in the Life Sciences research context and was validated for many multiplex assays in-house and with partners. MyCartis is a privately held company located in Ghent, Belgium.